Connection

Daniele Focosi to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Daniele Focosi has written about Antibodies, Monoclonal, Humanized.
Daniele Focosi
Connection Strength
0.254
Antibodies, Monoclonal, Humanized
  1. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
    View in: PubMed
    Score: 0.194
  2. SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. Viruses. 2021 06 23; 13(7).
    View in: PubMed
    Score: 0.048
  3. Introduction of SARS-COV-2 C.37 (WHO VOI lambda) from Peru to Italy. J Med Virol. 2021 Dec; 93(12):6460-6461.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.